{"filing":{"accession_number":"0001140361-26-027445","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"ef20077282_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/ef20077282_8k.htm"},"events":[{"id":15874,"run_id":14158,"accession_number":"0001140361-26-027445","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"BridgeBio entered into an Investment Agreement on July 1, 2026, under which Sixth Street Partners and HealthCare Royalty (a KKR affiliate) purchased $1 billion in Series A Cumulative Convertible Participating Preferred Stock, convertible into approximately 6.78 million common shares at an initial conversion price of $137.79 per share. This substantial private placement, relying on Section 4(a)(2) exemption, materially dilutes existing shareholders' ownership and voting power while strengthening the company's balance sheet.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13786,"accession_number":"0001140361-26-027445","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BridgeBio entered into an Investment Agreement on July 1, 2026, under which Sixth Street and HealthCare Royalty (KKR affiliate) purchased 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 million aggregate. The Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share, with conversion rights exercisable at any time. This represents a substantial dilutive equity issuance that will significantly increase the common share count upon conversion, materially affecting existing shareholders' ownership percentages and earnings per share.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13787,"accession_number":"0001140361-26-027445","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BridgeBio issued $1 billion in Series A Cumulative Convertible Participating Preferred Stock to Sixth Street and HealthCare Royalty in a private placement relying on Section 4(a)(2) exemption. The preferred stock is convertible into 6,777,705 shares of common stock, representing a significant dilutive issuance. This is a material capital raise that strengthens the balance sheet and is disclosed under Item 3.02 (Unregistered Sales of Equity Securities).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13788,"accession_number":"0001140361-26-027445","item_number":"3.03","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BridgeBio issued $1 billion in Series A Cumulative Convertible Participating Preferred Stock to Sixth Street and HealthCare Royalty, with conversion rights at $137.79 per share (later $153.10). This is a material equity issuance that dilutes common shareholders' ownership and voting power, particularly given the convertible nature and the substantial capital raised. Item 3.03 explicitly notes that common shareholders' rights became \"subject to, and may be adversely affected by\" the preferred stock's rights, including dividend and liquidation preferences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13789,"accession_number":"0001140361-26-027445","item_number":"5.03","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BridgeBio filed a Certificate of Designations establishing Series A Cumulative Convertible Participating Preferred Stock in connection with a $1 billion preferred equity investment by Sixth Street and HealthCare Royalty. The preferred stock is convertible into common shares at an initial conversion price of $137.79 per share, representing a dilutive equity issuance. While technically a preferred equity instrument, the convertible feature and the substantial capital raise ($1 billion) make this a material dilutive issuance that would affect investor assessment of ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13790,"accession_number":"0001140361-26-027445","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"BridgeBio announced a $1 billion investment in newly issued convertible preferred equity by Sixth Street ($800M) and HealthCare Royalty ($133.9M). The Series A Cumulative Convertible Participating Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share, representing a dilutive equity issuance. This is a material capital raise that strengthens the balance sheet and is disclosed via press release in Item 7.01 (Regulation FD Disclosure), with the transaction itself referenced in Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13786,"accession_number":"0001140361-26-027445","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BridgeBio entered into an Investment Agreement on July 1, 2026, under which Sixth Street and HealthCare Royalty (KKR affiliate) purchased 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 million aggregate. The Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share, with conversion rights exercisable at any time. This represents a substantial dilutive equity issuance that will significantly increase the common share count upon conversion, materially affecting existing shareholders' ownership percentages and earnings per share.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-02"},{"id":13787,"accession_number":"0001140361-26-027445","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BridgeBio issued $1 billion in Series A Cumulative Convertible Participating Preferred Stock to Sixth Street and HealthCare Royalty in a private placement relying on Section 4(a)(2) exemption. The preferred stock is convertible into 6,777,705 shares of common stock, representing a significant dilutive issuance. This is a material capital raise that strengthens the balance sheet and is disclosed under Item 3.02 (Unregistered Sales of Equity Securities).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-02"},{"id":13788,"accession_number":"0001140361-26-027445","item_number":"3.03","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BridgeBio issued $1 billion in Series A Cumulative Convertible Participating Preferred Stock to Sixth Street and HealthCare Royalty, with conversion rights at $137.79 per share (later $153.10). This is a material equity issuance that dilutes common shareholders' ownership and voting power, particularly given the convertible nature and the substantial capital raised. Item 3.03 explicitly notes that common shareholders' rights became \"subject to, and may be adversely affected by\" the preferred stock's rights, including dividend and liquidation preferences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-02"},{"id":13789,"accession_number":"0001140361-26-027445","item_number":"5.03","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BridgeBio filed a Certificate of Designations establishing Series A Cumulative Convertible Participating Preferred Stock in connection with a $1 billion preferred equity investment by Sixth Street and HealthCare Royalty. The preferred stock is convertible into common shares at an initial conversion price of $137.79 per share, representing a dilutive equity issuance. While technically a preferred equity instrument, the convertible feature and the substantial capital raise ($1 billion) make this a material dilutive issuance that would affect investor assessment of ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-02"},{"id":13790,"accession_number":"0001140361-26-027445","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"BridgeBio announced a $1 billion investment in newly issued convertible preferred equity by Sixth Street ($800M) and HealthCare Royalty ($133.9M). The Series A Cumulative Convertible Participating Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share, representing a dilutive equity issuance. This is a material capital raise that strengthens the balance sheet and is disclosed via press release in Item 7.01 (Regulation FD Disclosure), with the transaction itself referenced in Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:24:56.808423+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-02"}]}